Provided herein are isoergoline compounds and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and pharmaceutical compositions disclose
Provided herein are isoergoline compounds and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1A, 5-HT1B and 5-HT1D receptors without agonizing the 5-HT2B receptor using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HT2B adrenergic alpha2A and/or the alpha2B receptors using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the D2 and D3 receptor using the compounds and pharmaceutical compositions disclosed herein.
대표청구항▼
1. A compound of structural Formula (IV): or salts thereof, wherein:X is —NR8—;R1 is independently selected from hydrogen, alkyl, halo, or haloalkyl;R8 is independently selected from alkyl or haloalkyl; orR1 and R8 along with the atoms to which they are attached form a 5, 6 or 7 membered ring;R3 is
1. A compound of structural Formula (IV): or salts thereof, wherein:X is —NR8—;R1 is independently selected from hydrogen, alkyl, halo, or haloalkyl;R8 is independently selected from alkyl or haloalkyl; orR1 and R8 along with the atoms to which they are attached form a 5, 6 or 7 membered ring;R3 is independently selected from hydrogen or alkyl;R4 and R5 are hydrogen or;R4 and R5, together with the atoms to which they are joined form a double bond;R7 is R10 is independently selected from unsubstituted alkyl, or substituted alkyl;b is 1, 2, 3, or 4;Y is —OR12; andR12 is independently selected from hydrogen or alkyl. 2. The compound of claim 1, wherein R3 is methyl. 3. The compound of claim 2, wherein R4 and R5, together with the atoms to which they are joined form a double bond. 4. The compound of claim 3, wherein R1 is hydrogen, halo, or cyclopropyl. 5. The compound of claim 4, wherein R1 is hydrogen. 6. The compound of claim 3, wherein R1 and R8 along with the atoms to which they are attached form a 5 membered ring. 7. The compound of claim 4, wherein R10 is haloalkyl. 8. The compound of claim 5, wherein R10 is haloalkyl. 9. The compound of claim 6, wherein R10 is haloalkyl. 10. The compound of claim 7, wherein R10 is —CF2CF3. 11. The compound of claim 8, wherein R12 is hydrogen and b is 1. 12. The compound of claim 1 having the following structural formula:
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (123)
Sauer Gerhard (Berlin DEX) Wachtel Helmut (Berlin DEX) Lschmann Peter A. (Berlin DEX), 2,14-disubstituted ergolines, their production and use in pharmaceutical compositions.
Leland F. Wilson ; Paul C. Doherty, Jr. ; Virgil A. Place ; William L. Smith ; Ibrahim AbouBakr Abdel-Hamid Abdou Ali EG, Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation.
Cincotta Anthony H. (Andover MA) Meier Albert H. (Baton Rouge LA) Wilson John M. (Charlestown MA), Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metab.
Yuzhakov Vadim Vladimirovich ; Sherman Faiz Feisal ; Owens Grover David ; Gartstein Vladimir, Apparatus and method for using an intracutaneous microneedle array.
Tam, Peter; Gesundheit, Neil; Wilson, Leland F., As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation.
Oh, Jong Eun; Lee, Keon Hyoung; Park, Tae Gwan; Nam, Yoon Sung, Controlled drug delivery system using the conjugation of drug to biodegradable polyester.
Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Controlled release formulations coated with aqueous dispersions of acrylic polymers.
Marshall Lucia G. I. (St. Charles MO) Patel Kanaiyalal R. (St. Louis MO) Roufa Dikla G. (St. Louis MO), Controlled release formulations of trophic factors in ganglioside-lipsome vehicle.
Yatvin Milton B. ; Stowell Michael H. B. ; Gallicchio Vincent S. ; Meredith Michael J., Covalent microparticle-drug conjugates for biological targeting.
Mohr Judy M. (Menlo Park CA) Baker Richard W. (Palo Alto CA) Nakaji Lisa A. (San Jose CA), Liquid reservoir transdermal patch for the administration of ketorolac.
Doherty ; Jr. Paul C. ; Place Virgil A. ; Smith William L., Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction.
Doherty ; Jr. Paul C. ; Place Virgil A. ; Smith William L., Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction.
Doherty ; Jr. Paul C. ; Place Virgil A. ; Smith William L., Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction.
Calanchi Massimo,ITX ; Zema Marco,ITX ; Brunetti Gabriele,ITX ; Giorgetti Enzo,ITX, Method for targeted and controlled release of drugs in the intestinal tract and more particularly in the colon.
Cerny Antonin (Prague CSX) Krepelka Jiri (Prague CSX) Rezabek Karel (Prague CSX) Fruhaufova Maria (Prague CSX) Pesak Milan (Prague CSX) Sevcik Bohumil (Jilove u Prahy CSX) Kral Josef (Jilove u Prahy , Method for treatment of endometritis in mammalian females.
Santus Giancarlo (Milan ITX) Bilato Ettore (Padua ITX) Lazzarini Gabriele (Pero ITX), Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension.
Le Grazie Cristina (Milan ITX), Pharmaceutical compositions containing 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid and their pharmaceutic.
Venkateshwaran Srinivasan ; Fikstad David ; Ebert Charles D., Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents.
Barbosa, Antonio J. M.; Blomgren, Peter A.; Currie, Kevin S.; Krishnamoorthy, Ravi; Kropf, Jeffrey E.; Lee, Seung H.; Mitchell, Scott A.; Ortwine, Daniel; Schmitt, Aaron C.; Wang, Xiaojing; Xu, Jianjun; Young, Wendy; Zhang, Honglu; Zhao, Zhongdong; Zhichkin, Pavel E., Pyridone and aza-pyridone compounds and methods of use.
Eppstein Deborah A. (Los Altos CA) Fraser-Smith Elizabeth B. (Los Altos CA) Matthews Thomas R. (Los Gatos CA), Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides.
Brennan, Anthony B.; Long, Christopher James; Bagan, Joseph W.; Schumacher, James Frederick; Spiecker, Mark M., Surface topographies for non-toxic bioadhesion control.
Brennan, Anthony B; Baney, Ronald H.; Carman, Michelle L.; Estes, Thomas G.; Feinberg, Adam W.; Wilson, Leslie H.; Schumacher, James F., Surface topographies for non-toxic bioadhesion control.
Saikawa, Akira; Igari, Yasutaka; Hata, Yoshio; Yamamoto, Kazumichi, Sustained release compositions, process for producing the same and utilization thereof.
Bodmer David (Klingnau CHX) Fong Jones W. (Parsippany NJ) Kissel Thomas (Staufen DEX) Maulding Hawkins V. (Mendham NJ) Nagele Oskar (Sissach CHX) Pearson Jane E. (Ogendensburg NJ), Sustained release formulations of water soluble peptides.
Unger Evan C. ; Fritz Thomas A. ; Matsunaga Terry ; Ramaswami VaradaRajan ; Yellowhair David ; Wu Guanli, Targeted gas and gaseous precursor-filled liposomes.
Friend David R. ; Ng Steve ; Sarabia Rafael E. ; Weber Thomas P. ; Geoffroy Jean-Marie, Taste-masked microcapsule compositions and methods of manufacture.
Norris James ; Clawson Gary ; Westwater Caroline ; Schofield David ; Schmidt Michael ; Hoel Brian ; Dolan Joseph ; Pan Wei-Hua, Tissue-specific and pathogen-specific toxic agents and ribozymes.
Doherty, Jr., Paul C.; Place, Virgil A.; Smith, William L., Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.